In all, the use of BCL2 inhibitor alone may fail to achieve a satisfactory effect in lymphoma, but the combined use of BCL2 inhibitor and other DHL-BCL2 targeted drugs is promising, especially in BCL2 aberrant DLBCLs. Here, BCL2 is linked to lymphoma.